Recent News

• 02.27.2026 - A Multicenter, Randomized, Double-Blind Phase 3 Study of Palbociclib (Oral CDK 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole for the Treatment of Previously Untreated Asian Postmenopausal Women With ER (+), HER2 (-) Advanced Breast Cancer
• 02.18.2026 - An Open-label Extension Study to Evaluate the Long-term Safety of Osivelotor Administered to Participants With Sickle Cell Disease Who Have Participated in an Osivelotor Clinical Trial
• 02.18.2026 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Modified RNA Vaccines Against Influenza in Healthy Adults
• 02.03.2026 - Here’s How Pfizer is Fighting Cancer – and How You Can, Too

Recent Filings

• 02.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.26.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.24.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.24.2026 - 4 Statement of changes in beneficial ownership of securities